A Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-Azacitidine in AML

Trial Profile

A Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-Azacitidine in AML

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Azacitidine (Primary) ; Everolimus (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 14 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top